Cardiac implant and methods

Abstract

Cardiac implants include a conduit or scaffold having a first therapeutic agent in at least partial covering relation to at least a first portion of the scaffold, and a second therapeutic agent, different from the first therapeutic agent, in at least partial covering relation to at least a second portion of the scaffold. The first therapeutic agent and second therapeutic agent may include one of: antithrombotic agents, anti-inflammatory agents, antiproliferative agents, antibiotic agents, angiogenic agents, antiplatelet agents, anticoagulant agents, rhestenosis preventing agents, hormones and combinations thereof. Methods for making cardiac implants include providing a scaffold, covering at least a first portion of the scaffold with a first therapeutic agent, and covering at least a second portion of the scaffold, different from the first portion, with a second therapeutic agent different from the first therapeutic agent. Methods for treating a patient and for using cardiac implants include forming a blood flow path from a heart chamber directly to the coronary vessel, which includes placing a conduit in a heart wall between the chamber and the vessel with the first end of the conduit protruding into the chamber and protruding beyond an interior surface of the heart wall. The conduit will include a first therapeutic agent in covering relation to at least a first portion of the conduit and a second therapeutic agent in covering relation to at least a second portion.

1 - 38 . (canceled)  
     
     
         39 . A transmyocardial implant for defining a blood flow pathway directly from a heart chamber through a heart wall to a coronary vessel, the implant comprising: 
 a conduit having an open first end, an opposite open second end, an exterior surface, and an interior surface defining an open interior volume, the open interior volume being configured to accommodate blood flow between the open first end and the open second end;    an endothelium treatment in at least partial covering relation to at least a portion of the interior surface; and    a tissue growth-inducing material in at least partial covering relation to at least a portion of the exterior surface.    
     
     
         40 . The implant of  claim 39 , wherein the heart chamber is a left ventricle.  
     
     
         41 . The implant of  claim 39 , wherein the coronary vessel is a coronary artery.  
     
     
         42 . The implant of  claim 39 , wherein the implant is L-shaped.  
     
     
         43 . The implant of  claim 42 , wherein a leg of the L-shaped implant is sized to be received within a lumen of the coronary vessel.  
     
     
         44 . The implant of  claim 42 , wherein a leg of the L-shaped implant is sized to pass through the myocardium and extend into the heart chamber.  
     
     
         45 . The implant of  claim 39 , wherein the implant is configured to remain open during both systole and diastole.  
     
     
         46 . The implant of  claim 39 , further comprising an angiogenic agent in at least partial covering relation to at least a portion of the exterior surface.  
     
     
         47 . The implant of  claim 39 , further comprising a sleeve covering at least a portion of at least one of the interior surface and the exterior surface.  
     
     
         48 . The implant of  claim 47 , wherein at least one of the endothelium treatment and the tissue growth-inducing material is disposed on the sleeve.  
     
     
         49 . A transmyocardial implant for defining a blood flow pathway directly from a heart chamber through a heart wall to a coronary vessel, the implant comprising: 
 a conduit having an open first end, an opposite open second end, an exterior surface, and an interior surface defining an open interior volume, the open interior volume being configured to accommodate blood flow between the open first end and the open second end;    an endothelium treatment in at least partial covering relation to at least a portion of the interior surface; and    an angiogenic agent in at least partial covering relation to at least a portion of the exterior surface.    
     
     
         50 . The implant of  claim 49 , wherein the heart chamber is a left ventricle.  
     
     
         51 . The implant of  claim 49 , wherein the coronary vessel is a coronary artery.  
     
     
         52 . The implant of  claim 49 , wherein the implant is L-shaped.  
     
     
         53 . The implant of  claim 52 , wherein a leg of the L-shaped implant is sized to be received within a lumen of the coronary vessel.  
     
     
         54 . The implant of  claim 52 , wherein a leg of the L-shaped implant is sized to pass through the myocardium and extend into the heart chamber.  
     
     
         55 . The implant of  claim 49 , wherein the implant is configured to remain open during both systole and diastole.  
     
     
         56 . The implant of  claim 49 , further comprising a sleeve covering at least a portion of at least one of the interior surface and the exterior surface.  
     
     
         57 . The implant of  claim 56 , wherein at least one of the endothelium treatment and the angiogenic agent is disposed on the sleeve.